Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.

@article{Thelma2008GeneticUO,
  title={Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.},
  author={B. K. Thelma and Vibhuti Srivastava and Arun Kumar Tiwari},
  journal={Pharmacogenomics},
  year={2008},
  volume={9 9},
  pages={
          1285-306
        }
}
Manifestation of tardive dyskinesia (TD) among schizophrenia subjects on long-term antipsychotic treatment with typical drugs has been a clinical concern. Despite its association with extrapyramidal symptoms, typical drugs are still routinely prescribed globally though marginally superior atypical drugs have long been available. The genetic component in the etiology of TD is well documented. Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2… CONTINUE READING
BETA

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

New and emerging treatments for symptomatic tardive dyskinesia

  • Drug design, development and therapy
  • 2013
VIEW 6 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED